Edesa Biotech, Inc. financial data

Symbol
EDSA on Nasdaq
Industry
Pharmaceutical Preparations
Location
100 Spy Court, Markham, Ontario, Canada
State of incorporation
British Columbia, Canada
Fiscal year end
September 30
Former names
Stellar Biotechnologies, Inc. (to 5/30/2019)
Latest financial report
10-Q - Q4 2024 - Feb 14, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 134 % -65.6%
Debt-to-equity 55.5 % +192%
Return On Equity -214 % -106%
Return On Assets -124 % -48.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 3.47M shares +9.57%
Common Stock, Shares, Outstanding 3.47M shares +9.57%
Entity Public Float 11.1M USD
Common Stock, Value, Issued 47.6M USD +1.34%
Weighted Average Number of Shares Outstanding, Basic 3.35M shares +6.94%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 3.2M USD -22.8%
General and Administrative Expense 3.86M USD -15.4%
Operating Income (Loss) -7.06M USD +18.9%
Nonoperating Income (Expense) 948K USD -3.73%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -1.67M USD +16%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -6.11M USD +20.9%
Earnings Per Share, Basic -0.48 USD/shares +11.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 1.6M USD
Assets, Current 2.07M USD -61.7%
Property, Plant and Equipment, Net 0 USD -100%
Operating Lease, Right-of-Use Asset 0 USD -100%
Intangible Assets, Net (Excluding Goodwill) 2.21M USD
Assets 4.16M USD -46.8%
Liabilities, Current 1.9M USD -4.36%
Operating Lease, Liability, Noncurrent 0 USD -100%
Liabilities 1.83M USD -0.48%
Accumulated Other Comprehensive Income (Loss), Net of Tax -224K USD -4.06%
Retained Earnings (Accumulated Deficit) -60.2M USD -11.3%
Stockholders' Equity Attributable to Parent 2.26M USD -61.3%
Liabilities and Equity 4.16M USD -46.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.52M USD -7.87%
Net Cash Provided by (Used in) Financing Activities 2.07M USD +578%
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares, Issued 3.47M shares +9.57%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 526K USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 1.56M USD -63.4%
Deferred Tax Assets, Valuation Allowance 18.1M USD +9.77%
Deferred Tax Assets, Gross 18.2M USD +8.99%
Operating Lease, Liability 19.9K USD -79%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -6.12M USD +20.5%
Lessee, Operating Lease, Liability, to be Paid 20K USD -79.9%
Property, Plant and Equipment, Gross 52.5K USD 0%
Operating Lease, Liability, Current 0 USD -100%
Lessee, Operating Lease, Liability, to be Paid, Year Two 20K USD -0.1%
Lessee, Operating Lease, Liability, to be Paid, Year One 20K USD -74.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 152 USD
Preferred Stock, Shares Issued 150 shares
Operating Lease, Payments 17.9K USD -11.1%
Additional Paid in Capital 14.2M USD +7.21%
Amortization of Intangible Assets 30K USD 0%
Depreciation, Depletion and Amortization 43.1K USD -4.27%
Deferred Tax Assets, Net of Valuation Allowance 126K USD -45.9%